Tony Berberabe, MPH | Authors

Regorafenib Plus Pembrolizumab Combo Misses PFS End Point, Shows Strong OS for MSS Colorectal Cancer

January 22, 2022

Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.